Stockscreener 앱 받기
0.219
3.99%
-0.0091
시장 영업 전:
.22
0.001
+0.46%
전일 마감가:
$0.2281
열려 있는:
$0.225
하루 거래량:
837.63K
Relative Volume:
1.35
시가총액:
$17.79M
수익:
$3.38M
순이익/손실:
$-15.06M
주가수익비율:
-0.9339
EPS:
-0.2345
순현금흐름:
$-15.50M
1주 성능:
-6.81%
1개월 성능:
-18.92%
6개월 성능:
-69.66%
1년 성능:
-78.74%
1일 변동 폭
$0.2123
$0.229
1주일 범위
$0.2123
$0.2377
52주 변동 폭
$0.2123
$1.40
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
0.219 | 18.53M | 3.38M | -15.06M | -15.50M | -0.2345 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Icecure Medical Ltd 주식(ICCM)의 최신 뉴스
Why Has IceCure Medical's Stock Price Collapsed - Kavout
Number of shareholders of IceCure Medical Ltd. – BOATS:ICCM - TradingView
Icecure Medical Ltd (ICCM) Q1 2026 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Icecure Medical Ltd (ICCM) Q1 2026 Earnings Call Highlights: Rob - GuruFocus
Icecure Medical Earnings Call Highlights Growth Momentum - TipRanks
IceCure Medical presents positive ProSense cryoablation data - grafa.com
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for - GuruFocus
IceCure Showcases Strong ProSense® Cryoablation Data and Surge in Clinical Interest at ECIO 2026 - TipRanks
IceCure Medical (ICCM) highlights kidney and breast cryoablation data at ECIO 2026 - Stock Titan
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked - PR Newswire
IceCure Medical Ltd. Reports Nearly 90% Recurrence-Free Rate For Cryoablation Of Kidney Cancer And Showcases ProSense At ECIO 2026 - marketscreener.com
[Form 4] IceCure Medical Ltd. Insider Trading Activity - Stock Titan
IceCure Medical : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
IceCure Medical (ICCM) CFO reports 400,000 RSUs equity grant - Stock Titan
IceCure Medical Ltd. (ICCM) reports Q1 loss, lags revenue estimates - MSN
IceCure Medical Ltd.Ordinary Shares (NQ: ICCM - The Chronicle-Journal
Maxim Group Maintains Icecure Medical(ICCM.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Maxim Group Maintains Icecure Medical(ICCM.US) With Buy Rating, Cuts Target Price to $1 - Moomoo
ICCM Maintained by Maxim Group -- Price Target Lowered to $1.00 - GuruFocus
IceCure Medical Wins Nasdaq Extension to Restore Minimum Bid Compliance - The Globe and Mail
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - The Malaysian Reserve
Icecure granted 180-day extension by Nasdaq to regain compliance with minimum bid requirement - marketscreener.com
IceCure Medical (ICCM) wins new 180-day window to meet Nasdaq $1 bid - Stock Titan
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Requirement - Moomoo
IceCure Medical Ltd (NASDAQ:ICCM) Q1 2026 Earnings Call Transcript - Insider Monkey
IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America - StreetInsider
ICECURE MEDICAL ($ICCM) Releases Q1 2026 Earnings - Moomoo
[424B5] IceCure Medical Ltd. Prospectus Supplement (Debt Securities) - Stock Titan
IceCure Medical Sets Up At-the-Market Equity Program With A.G.P./Alliance Global Partners - TipRanks
[6-K] IceCure Medical Ltd. Current Report (Foreign Issuer) | ICCM SEC FilingForm 6-K - Stock Titan
ICCM: Strong Q1 Revenue Growth Signals Positive Market Momentum - GuruFocus
IceCure (ICCM) Q1 2026 Earnings Transcript - AOL.com
IceCure Reports First Quarter 2026 Financial Results: ProSense® - GuruFocus
ICCM: Q1 2026 revenue up 26% year-over-year, driven by U.S. growth and post-FDA commercial momentum - TradingView
ICCM: Q1 2026 saw 26% revenue growth and accelerating U.S. adoption following FDA clearance - TradingView
ICCM: ProSense® sales soared post-FDA clearance, fueling robust revenue growth and U.S. adoption - TradingView
IceCure Medical Posts Strong Q1 2026 ProSense® Growth in U.S. After FDA Clearance - TipRanks
IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates - Eastern Progress
IceCure Medical (NASDAQ: ICCM) grows Q1 2026 revenue but posts $4.3M loss - Stock Titan
IceCure Medical (NASDAQ:ICCM) Shares Slide Over 7% Premarket After Q1 Revenue Miss - ChartMill
Press Release: IceCure Reports First Quarter 2026 Financial Results: ProSense(R) Sales Increase Substantially in the U.S. and North America - Moomoo
IceCure Medical Q1 2026 Earnings Call Transcript - MarketBeat
IceCure Medical Shareholders Approve Agenda Item at May 11 Special Meeting After Initial Adjournment - TipRanks
IceCure Medical (ICCM) shareholders approve agenda item after adjourned meeting - Stock Titan
ICCM Stock Price, Quote & Chart | ICECURE MEDICAL LTD (NASDAQ:ICCM) - ChartMill
IceCure Medical Faces Certified Class Action in Israel Over 2021 Private Placement - TipRanks
IceCure Medical to Release First Quarter 2026 Financial Results on May 12 - geneonline.com
IceCure to release Q1 results before market, webcast at 11 a.m. EDT - Stock Titan
IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026 - marketscreener.com
IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market - Quantisnow
A. G. P. Initiates Icecure Medical(ICCM.US) With Buy Rating, Announces Target Price $1 - Moomoo
Icecure Medical Ltd (ICCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
1.94%
자본화:
|
볼륨(24시간):